Hormonal Therapy
Key Points
- Hormonal therapy (HT/HRT) replaces estrogen (and sometimes progestin) that decreases during menopause — relieves hot flashes, vaginal dryness, night sweats, and mood changes.
- FDA Black Box Warning: Estrogen (alone or combined with progestin) significantly increases risks of stroke, MI, DVT, PE, and invasive breast cancer in postmenopausal women — use the lowest effective dose for the shortest duration needed.
- Conjugated estrogen (Premarin) oral HRT: 0.3–0.625 mg/day orally (25 days on / 5 days off).
- Combined therapy (estrogen + progestin) is recommended for women with an intact uterus — estrogen-only therapy increases risk of endometrial cancer; progestin counteracts this.
- Contraindicated in women with history of breast cancer, DVT, PE, stroke, active liver disease, or estrogen-dependent neoplasia.
- Risk-benefit counseling should include age stratification: adverse events rise in women over 60, and treatment is generally favored only when symptom burden justifies risk.
- Menopause-symptom treatment is individualized; many healthy patients aged about 50 to 59 or within about 10 years of menopause can use HRT safely for limited duration when symptom burden is high.
Indications for Hormonal Therapy
Hormonal therapy replaces estrogen produced by the ovaries, which declines during perimenopause and ceases at menopause:
| Indication | Description |
|---|---|
| Menopausal symptoms | Hot flashes, night sweats, mood changes, insomnia, weight gain, thinning hair |
| Genitourinary syndrome of menopause | Vaginal dryness, dyspareunia (painful intercourse), urogenital atrophy |
| Primary ovarian failure / hypogonadism | Premature menopause from surgery, radiation, or genetic causes |
| Prevention of osteoporosis | Estrogen preserves calcium/phosphorus and stimulates bone growth — delays progression |
| Palliative cancer therapy | High-dose conjugated estrogen used in palliative treatment of advanced breast cancer (10 mg tid) or prostate cancer (1.25–2.5 mg tid) |
Hormonal Therapy Preparations
Estrogen-Only Therapy
Used in women who have had a hysterectomy (no uterus = no endometrial cancer risk from unopposed estrogen).
| Drug | Brand | Route | Dose |
|---|---|---|---|
| Conjugated estrogen | Premarin | Oral | 0.3–0.625 mg/day (25 days on / 5 days off) |
| Estradiol | Estrace | Oral | Initial: 0.5–2 mg orally once daily |
| Estradiol | Estraderm, Vivelle-Dot | Transdermal patch | Initial: 0.0375–0.05 mg/24 hours applied twice weekly |
| Estradiol | Divigel, Estrogel | Transdermal spray/gel | Initial: 1 spray (1.53 mg) once daily on forearm |
| Estradiol | — | Vaginal cream | 2–4 g daily vaginally for 1–2 weeks; then taper |
Combined Estrogen-Progestin Therapy
Required for women with an intact uterus — progestin protects the endometrium from estrogen-induced hyperplasia and cancer.
- Continuous combined: estrogen + progestin every day (no withdrawal bleeding)
- Sequential combined: estrogen daily + progestin for 10–14 days per month (cyclic withdrawal bleeding)
Progesterone is added to HRT to reduce endometrial cancer risk by counteracting estrogen’s proliferative effect on the endometrium.
Adverse Effects
| Effect | Notes |
|---|---|
| Weight gain, bloating | Hormonal fluid retention |
| Nausea, headaches | Especially with oral forms |
| Breast tenderness | May resolve over time |
| Depression, mood changes | Assess and report |
| Thromboembolic events | DVT, PE — serious; assess for leg pain, swelling, SOB |
| Cardiovascular events | MI, stroke — most serious risks in older postmenopausal women |
| Breast cancer | Combined E+P therapy increases invasive breast cancer risk |
| Endometrial cancer | Estrogen-only therapy in women with uterus — prevented by adding progestin |
Black Box Warnings
FDA Black Box Warning: Estrogen / Estrogen-Progestin
- Cardiovascular events: Significantly increased risk of stroke and heart attack in postmenopausal clients
- Invasive breast cancer: Significantly increased risk of invasive breast cancer with combined estrogen-progestin therapy
- Dementia: Should NOT be used to prevent dementia — may actually increase risk
- Principle: Use lowest effective dose for shortest duration needed
Contraindications
| Contraindication | Rationale |
|---|---|
| Breast cancer (known or suspected) | Estrogen stimulates hormone-receptor-positive tumor growth |
| History of DVT, PE, or stroke | Estrogen increases clotting risk further |
| Active or history of cardiovascular disease | Increases MI and stroke risk |
| Undiagnosed abnormal uterine bleeding | May indicate endometrial pathology |
| Pregnancy | Estrogen crosses placenta |
| Active liver disease | Impaired estrogen metabolism |
| Estrogen-dependent neoplasia | Stimulates tumor growth |
| Protein C, S, or antithrombin deficiency | Thrombophilic disorder — high clotting risk |
Use with caution: Women >35 years who smoke (cardiovascular risk).
Drug Interactions
- CYP450 inducers reduce effectiveness: barbiturates, carbamazepine, phenytoin, rifampin, St. John’s wort
- Antibiotics (penicillin, tetracyclines) may reduce effectiveness
- Grapefruit: may increase estrogen levels
- Ketoconazole may increase estrogen levels
- Some SSRIs can reduce tamoxifen activation; avoid interacting SSRI pathways in patients using tamoxifen.
Nursing Assessment
NCLEX Focus
Key nursing priorities for HRT: (1) screen for absolute contraindications (DVT, stroke, breast cancer) before prescribing; (2) teach ACHES-like warning signs (chest pain, leg swelling/pain, visual changes, severe headache, SOB) as indicators of thromboembolism; (3) use lowest dose for shortest duration.
- Complete history: personal and family history of breast cancer, clotting disorders, cardiovascular disease, liver disease, smoking
- Assess current blood pressure — hypertension is a relative contraindication
- Confirm no undiagnosed abnormal uterine bleeding
- Assess for estrogen-dependent cancer history
Nursing Interventions and Patient Education
- Teach patient to report immediately: chest pain, leg pain or swelling, sudden shortness of breath, visual changes, severe headache — signs of thromboembolism
- Regular breast self-exams and mammography — breast cancer screening is essential during HRT
- HRT is not recommended for primary prevention of cardiovascular disease or dementia
- Transdermal preparations are associated with lower clotting risk than oral forms — may be preferred in at-risk patients
- Educate on correct application of transdermal patch: rotate sites, apply to clean dry skin (abdomen or upper outer arm), press for 10 seconds
- For injectable oil-based hormone formulations (for example selected testosterone/estrogen/progesterone regimens), use route/site-specific IM technique, larger-bore needles when needed (often 18G-21G), and rotate injection sites to reduce painful nodules.
- If nonhormonal vasomotor treatment is needed in patients with breast-cancer history on tamoxifen, verify antidepressant choice for tamoxifen-compatibility before initiation.
Related Concepts
- functional-reproductive-disorders — Hormone therapy is used for dysmenorrhea, endometriosis, and menopausal symptoms.
- combined-hormonal-contraceptives — Combined OCP uses estrogen + progestin in younger women; similar black box concerns apply.
- breast-cancer-care — Estrogen stimulates ER+ breast cancer — HRT is contraindicated with breast cancer history.
- progestin-only-contraceptives — Progestin addition to estrogen HRT protects against endometrial cancer.
Self-Check
- A postmenopausal woman with an intact uterus is prescribed estrogen-only HRT. What is the priority nursing concern, and what should be done?
- A patient on HRT reports sudden onset of left calf pain and swelling. What is the priority nursing action?
- A 58-year-old woman with a history of DVT requests HRT for severe hot flashes. How should the nurse respond?